Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)

The recruitment status of this study is unknown because the information has not been verified recently.

Verified January 2010 by Shaheed Beheshti Medical University.
Recruitment status was Recruiting

Sponsor:

Collaborator:

Ophthalmic Research Center

Information provided by:

Shaheed Beheshti Medical University

ClinicalTrials.gov Identifier:

NCT01178697

First received: August 2, 2010

Last updated: August 9, 2010

Last verified: January 2010

History of Changes

Tracking Information
First Received Date ^ICMJE	August 2, 2010
Last Updated Date	August 9, 2010
Start Date ^ICMJE	January 2010
Estimated Primary Completion Date	September 2010 (final data collection date for primary outcome measure)
Current Primary Outcome Measures ^ICMJE (submitted: August 9, 2010)	Visual acuity [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Original Primary Outcome Measures ^ICMJE	Same as current
Change History	Complete list of historical versions of study NCT01178697 on ClinicalTrials.gov Archive Site
Current Secondary Outcome Measures ^ICMJE (submitted: August 9, 2010)	central macular thickness [ Time Frame: 6 months ] [ Designated as safety issue: No ]
Original Secondary Outcome Measures ^ICMJE	Same as current
Current Other Outcome Measures ^ICMJE	Not Provided
Original Other Outcome Measures ^ICMJE	Not Provided

Descriptive Information
Brief Title ^ICMJE	Intravitreal Bevasizumab Versus Intravitreal Triamcinolone in Central Retinal Vein Occlusion (CRVO)
Official Title ^ICMJE	Three Injections of Intravitreal Bevasizumab Versus Two Injections of Intravitreal Triamcinolone in the Management of Branch Retinal Vein Occlusion
Brief Summary	This randomized clinical trial is conducted to evaluate the effect of three intravitreal injections of bevasizumab versus two intravitreal injections of triamcinolone in acute central retinal vein occlusion. The outcomes are visual acuity and central macular thickness. The follow-up time is 6 months.
Detailed Description	Not Provided
Study Type ^ICMJE	Interventional
Study Phase	Phase 2
Study Design ^ICMJE	Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Masking: Single Blind (Investigator) Primary Purpose: Treatment
Condition ^ICMJE	Central Retinal Vein Occlusion
Intervention ^ICMJE	Drug: Bevasizumab Intravitreal, 1.25 mg, 3 times, one month apart. Drug: Triamcinolone Acetonide Intravitreal, 2 mg, 2 times, two months apart.
Study Arm (s)	Active Comparator: Intravitreal triamcinolone Intervention: Drug: Triamcinolone Acetonide Active Comparator: Intravitreal bevasizumab Intervention: Drug: Bevasizumab
Publications *	Not Provided
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.

Recruitment Information
Recruitment Status ^ICMJE	Recruiting
Enrollment ^ICMJE	Not Provided
Estimated Completion Date	December 2010
Estimated Primary Completion Date	September 2010 (final data collection date for primary outcome measure)
Eligibility Criteria ^ICMJE	Inclusion Criteria: Recent onset (less than 3 months) central retinal vein occlusion Exclusion Criteria: Any previous intervention
Gender	Both
Ages	Not Provided
Accepts Healthy Volunteers	Not Provided
Contacts ^ICMJE	Not Provided
Location Countries ^ICMJE	Iran, Islamic Republic of

Administrative Information
NCT Number ^ICMJE	NCT01178697
Other Study ID Numbers ^ICMJE	8886
Has Data Monitoring Committee	Not Provided
Responsible Party	Not Provided
Study Sponsor ^ICMJE	Shaheed Beheshti Medical University
Collaborators ^ICMJE	Ophthalmic Research Center
Investigators ^ICMJE	Not Provided
Information Provided By	Shaheed Beheshti Medical University
Verification Date	January 2010
^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

To Top